Nippon Genetics Europe

nippongenetics.eu

Nippon Genetics Europe is the European subsidiary of Nippon genetics Co. Ltd. in Japan. We are focused on the manufacturing, sales and marketing of products for the Life Science community. The Japanese company was founded in 1988 in Tokyo and Kyoto, whereas the German office started on January 2005 Our customers are scientists working at universities and research institutes, pharmaceutical and biotech companies and/or clinical labs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy, Industrial Impact

EVAXION AND PANTHERNA REVEALS PROMISING PRECLINICAL PROOF OF CONCEPT FOR COMBINED TECHNOLOGIES

Evaxion | February 10, 2023

news image

Evaxion Biotech A/S, a clinical-phase biotech company specializing in enhancing AI-powered immunotherapies, and Pantherna Therapeutics GmbH, a biopharmaceutical company developing enhanced nanoparticle solutions for delivering and expressing mRNA therapeutics, announced a preclinical proof of concept for the combination of their key technologies. Using Pantherna's unique lipid nanoparticle mRNA technology (PTXLNP®, PTXmRNA®), tumor neoantigens discovered by Evaxion&#...

Read More

NOVARTIS TAPS ORIONIS TO PURSUE 'HISTORICALLY ELUSIVE TARGETS'

FierceBiotech | March 06, 2020

news image

Novartis has entered into a four-year research collaboration with Orionis Biosciences. The agreement tasks Orionis with applying its technologies to “historically elusive targets” in multiple therapeutic areas. Orionis has been around since 2015 but kept a low profile over most of that time. The transatlantic biotech used its time flying below the radar to establish two platforms, one focused on cytokines and another for “genome-scale drug discovery,” and to use them to g...

Read More

ACTICOR BIOTECH ANNOUNCES THE SUCCESS OF THE FIRST PHASE OF ITS ACTIMIS STUDY WITH GLENZOCIMAB IN PATIENTS WITH ACUTE ISCHEMIC STROKE

Acticor Biotech | October 05, 2020

news image

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced the completion of its ACTIMIS Dose Escalation Phase of Glenzocimab Study as add-on to standard of care in Patients with acute ischemic stroke. This Dose Escalation Phase was successfully completed with 60 patients enrolled from 6 European countries (France, Belgium, Germany, Spain, Switzerland and Italy). 5 cohorts of patients presenting wit...

Read More

Industry Outlook

FOXO TECHNOLOGIES LAUNCHES BIOINFORMATICS SERVICES TO REVOLUTIONIZE EPIGENETIC DATA ANALYSIS

Businesswire | July 20, 2023

news image

FOXO Technologies Inc.™ a leader in the field of commercializing epigenetic biomarker technology, announced the launch of its cutting-edge Bioinformatics Services to accelerate breakthroughs in biology, biotechnology, and healthcare, and redefine the growing field of epigenetic research. FOXO’s Bioinformatics Services offers a comprehensive platform of advanced data solutions tailored to meet the specific needs of clients in academia, healthcare, and pharmaceutical r...

Read More
news image

Cell and Gene Therapy, Industrial Impact

EVAXION AND PANTHERNA REVEALS PROMISING PRECLINICAL PROOF OF CONCEPT FOR COMBINED TECHNOLOGIES

Evaxion | February 10, 2023

Evaxion Biotech A/S, a clinical-phase biotech company specializing in enhancing AI-powered immunotherapies, and Pantherna Therapeutics GmbH, a biopharmaceutical company developing enhanced nanoparticle solutions for delivering and expressing mRNA therapeutics, announced a preclinical proof of concept for the combination of their key technologies. Using Pantherna's unique lipid nanoparticle mRNA technology (PTXLNP®, PTXmRNA®), tumor neoantigens discovered by Evaxion&#...

Read More
news image

NOVARTIS TAPS ORIONIS TO PURSUE 'HISTORICALLY ELUSIVE TARGETS'

FierceBiotech | March 06, 2020

Novartis has entered into a four-year research collaboration with Orionis Biosciences. The agreement tasks Orionis with applying its technologies to “historically elusive targets” in multiple therapeutic areas. Orionis has been around since 2015 but kept a low profile over most of that time. The transatlantic biotech used its time flying below the radar to establish two platforms, one focused on cytokines and another for “genome-scale drug discovery,” and to use them to g...

Read More
news image

ACTICOR BIOTECH ANNOUNCES THE SUCCESS OF THE FIRST PHASE OF ITS ACTIMIS STUDY WITH GLENZOCIMAB IN PATIENTS WITH ACUTE ISCHEMIC STROKE

Acticor Biotech | October 05, 2020

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced the completion of its ACTIMIS Dose Escalation Phase of Glenzocimab Study as add-on to standard of care in Patients with acute ischemic stroke. This Dose Escalation Phase was successfully completed with 60 patients enrolled from 6 European countries (France, Belgium, Germany, Spain, Switzerland and Italy). 5 cohorts of patients presenting wit...

Read More
news image

Industry Outlook

FOXO TECHNOLOGIES LAUNCHES BIOINFORMATICS SERVICES TO REVOLUTIONIZE EPIGENETIC DATA ANALYSIS

Businesswire | July 20, 2023

FOXO Technologies Inc.™ a leader in the field of commercializing epigenetic biomarker technology, announced the launch of its cutting-edge Bioinformatics Services to accelerate breakthroughs in biology, biotechnology, and healthcare, and redefine the growing field of epigenetic research. FOXO’s Bioinformatics Services offers a comprehensive platform of advanced data solutions tailored to meet the specific needs of clients in academia, healthcare, and pharmaceutical r...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us